{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:31:27Z","timestamp":1787859087067,"version":"build-2784847793"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":78,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006601","name":"Ministero degli Affari Esteri e della Cooperazione Internazionale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.jtauto.2020.100049","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T19:19:04Z","timestamp":1585682344000},"page":"100049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies"],"prefix":"10.1016","volume":"3","author":[{"given":"Angela","family":"Ceribelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Isailovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Gorlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtauto.2020.100049_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.1780230602","article-title":"Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome","volume":"23","author":"Tan","year":"1980","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jtauto.2020.100049_bib2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s10067-011-1751-0","article-title":"Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies","volume":"30","author":"Krzyszczak","year":"2011","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.jtauto.2020.100049_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A\u00a0comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"10","key":"10.1016\/j.jtauto.2020.100049_bib4","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3899\/jrheum.160106","article-title":"Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis","volume":"43","author":"Nandiwada","year":"2016","journal-title":"J.\u00a0Rheumatol."},{"issue":"3","key":"10.1016\/j.jtauto.2020.100049_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/s10165-009-0155-3","article-title":"Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases","volume":"19","author":"Satoh","year":"2009","journal-title":"Mod. Rheumatol."},{"issue":"10","key":"10.1016\/j.jtauto.2020.100049_bib6","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3899\/jrheum.100316","article-title":"Anti-Th\/To are common antinucleolar autoantibodies in Italian patients with scleroderma","volume":"37","author":"Ceribelli","year":"2010","journal-title":"J.\u00a0Rheumatol."},{"issue":"1","key":"10.1016\/j.jtauto.2020.100049_bib7","first-page":"104","article-title":"Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis","volume":"34","author":"Meyer","year":"2007","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jtauto.2020.100049_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2017.10.001","article-title":"Detection of anti-mitochondrial antibodies by immunoprecipitation in patients with systemic sclerosis","volume":"452","author":"Ceribelli","year":"2018","journal-title":"J.\u00a0Immunol. Methods"},{"issue":"11","key":"10.1016\/j.jtauto.2020.100049_bib9","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jtauto.2020.100049_bib10","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.7326\/0003-4819-119-10-199311150-00007","article-title":"Autoantibody reactive with RNA polymerase III in systemic sclerosis","volume":"119","author":"Okano","year":"1993","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.jtauto.2020.100049_bib11","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jtauto.2020.100049_bib12","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/art.39755","article-title":"Brief report: anti-eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis","volume":"68","author":"Betteridge","year":"2016","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jtauto.2020.100049_bib13","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/rheumatology\/kex458","article-title":"Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1\/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis","volume":"57","author":"Pauling","year":"2018","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.jtauto.2020.100049_bib14","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J.\u00a0Rheumatol."},{"issue":"1","key":"10.1016\/j.jtauto.2020.100049_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1752-699X.2010.00228.x","article-title":"Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease","volume":"6","author":"De Santis","year":"2012","journal-title":"Clin. Res. J"},{"issue":"2","key":"10.1016\/j.jtauto.2020.100049_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/ar628","article-title":"The clinical relevance of autoantibodies in scleroderma","volume":"5","author":"Ho","year":"2003","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.jtauto.2020.100049_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MD.0b013e31829be125","article-title":"Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature","volume":"92","author":"Gelber","year":"2013","journal-title":"Medicine (Baltim.)"},{"issue":"7","key":"10.1016\/j.jtauto.2020.100049_bib18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3899\/jrheum.101144","article-title":"Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies","volume":"38","author":"Airo","year":"2011","journal-title":"J.\u00a0Rheumatol."},{"issue":"8","key":"10.1016\/j.jtauto.2020.100049_bib19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2008.06.010","article-title":"Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies","volume":"7","author":"Koenig","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2020.100049_bib20","first-page":"98","article-title":"Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis","volume":"35","author":"Iniesta Arandia","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.jtauto.2020.100049_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181692","article-title":"Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Le Gouellec","year":"2017","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.jtauto.2020.100049_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.autrev.2010.09.012","article-title":"Interstitial lung disease in systemic sclerosis","volume":"10","author":"Bussone","year":"2011","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.jtauto.2020.100049_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00408-007-9012-3","article-title":"Interstitial lung disease in systemic sclerosis","volume":"185","author":"Ostojic","year":"2007","journal-title":"Lung"},{"issue":"2","key":"10.1016\/j.jtauto.2020.100049_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11926-007-0012-3","article-title":"Autoimmunity in systemic sclerosis: current concepts","volume":"9","author":"Boin","year":"2007","journal-title":"Curr. Rheumatol. Rep."},{"issue":"4","key":"10.1016\/j.jtauto.2020.100049_bib25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/14397595.2015.1115455","article-title":"Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: inception cohort study","volume":"26","author":"Wangkaew","year":"2016","journal-title":"Mod. Rheumatol."},{"issue":"11","key":"10.1016\/j.jtauto.2020.100049_bib26","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3899\/jrheum.171362","article-title":"Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis","volume":"45","author":"Showalter","year":"2018","journal-title":"J.\u00a0Rheumatol."},{"issue":"1","key":"10.1016\/j.jtauto.2020.100049_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13075-018-1545-8","article-title":"Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis","volume":"20","author":"Weigold","year":"2018","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.jtauto.2020.100049_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.autrev.2018.01.006","article-title":"Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype","volume":"17","author":"Fritzler","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"8","key":"10.1016\/j.jtauto.2020.100049_bib29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2018-214439","article-title":"Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes","volume":"78","author":"Spielmann","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.jtauto.2020.100049_bib30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00296-017-3893-0","article-title":"Interstitial lung disease in South Africans with systemic sclerosis","volume":"38","author":"Ashmore","year":"2018","journal-title":"Rheumatol. Int."},{"issue":"7","key":"10.1016\/j.jtauto.2020.100049_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.jtauto.2020.100049_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"5","key":"10.1016\/j.jtauto.2020.100049_bib33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/1744666X.3.5.721","article-title":"Clinical implication of autoantibodies in patients with systemic rheumatic diseases","volume":"3","author":"Satoh","year":"2007","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2020.100049_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085062","article-title":"The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia","volume":"9","author":"Nakashima","year":"2014","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.jtauto.2020.100049_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0002-9343(90)90149-8","article-title":"Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase)","volume":"88","author":"Targoff","year":"1990","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.jtauto.2020.100049_bib36","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.4049\/jimmunol.162.4.2315","article-title":"Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease","volume":"162","author":"Hirakata","year":"1999","journal-title":"J.\u00a0Immunol."},{"issue":"1","key":"10.1016\/j.jtauto.2020.100049_bib37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0049-0172(96)80026-6","article-title":"Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis","volume":"26","author":"Friedman","year":"1996","journal-title":"Semin. Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jtauto.2020.100049_bib38","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1378\/chest.08-2233","article-title":"Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature","volume":"135","author":"Kalluri","year":"2009","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.jtauto.2020.100049_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.jtauto.2020.100049_bib40","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejim.2013.01.002","article-title":"Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome","volume":"24","author":"Marie","year":"2013","journal-title":"Eur. J. Intern. Med."},{"issue":"4","key":"10.1016\/j.jtauto.2020.100049_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.jtauto.2020.100049_bib42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","article-title":"Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis","volume":"158","author":"Kobayashi","year":"2011","journal-title":"J.\u00a0Pediatr."},{"issue":"3","key":"10.1016\/j.jtauto.2020.100049_bib43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.jtauto.2020.100049_bib44","first-page":"891","article-title":"Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis","volume":"32","author":"Ceribelli","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.jtauto.2020.100049_bib45","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jtauto.2020.100049_bib46","first-page":"290797","article-title":"Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis","volume":"2014","author":"Labrador-Horrillo","year":"2014","journal-title":"J\u00a0Immunol Res"},{"issue":"5","key":"10.1016\/j.jtauto.2020.100049_bib47","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909020300162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909020300162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:34:06Z","timestamp":1762904046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909020300162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":47,"alternative-id":["S2589909020300162"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2020.100049","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2020.100049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100049"}}